AbbVie breaks ground on North Chicago API manufacturing facility

AbbVie (ABBV) announced the start of construction of its new active pharmaceutical ingredient manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie’s ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity. Active pharmaceutical ingredient manufacturing is a complex and multistep process that involves producing the active components responsible for medications’ therapeutic effects. When completed, AbbVie’s new North Chicago API facility will expand its chemical synthesis capabilities and enable AbbVie to bring API production for select products from Europe and Asia to the US to support domestic production of current and next generation neuroscience, immunology and oncology medicines. With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 employees in the U.S. The previously announced $195M investment in North Chicago will create new jobs and expand AbbVie’s existing U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites. This investment also furthers AbbVie’s long-term commitment to Illinois, where it is headquartered and includes more than 11,000 employees who work to develop and manufacture innovative medicines for patients worldwide.